Palisade Bio, Inc. (PALI)
1.24
+0.12
(+10.71%)
USD |
NASDAQ |
Nov 03, 16:00
1.24
0.00 (0.00%)
After-Hours: 18:07
Palisade Bio Enterprise Value : 69.26M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 69.26M |
| October 30, 2026 | 76.20M |
| October 29, 2026 | 81.41M |
| October 28, 2026 | 81.41M |
| October 27, 2026 | 83.14M |
| October 26, 2026 | 88.35M |
| October 23, 2026 | 105.71M |
| October 22, 2026 | 109.18M |
| October 21, 2026 | 117.86M |
| October 20, 2026 | 123.07M |
| October 19, 2026 | 107.45M |
| October 16, 2026 | 119.60M |
| October 15, 2026 | 142.17M |
| October 14, 2026 | 131.75M |
| October 13, 2026 | 129.15M |
| October 12, 2026 | 150.85M |
| October 09, 2026 | 142.17M |
| October 08, 2026 | 126.54M |
| October 07, 2026 | 131.75M |
| October 06, 2026 | 133.49M |
| October 05, 2026 | 128.28M |
| October 02, 2026 | 124.81M |
| October 01, 2026 | 123.07M |
| September 30, 2026 | 109.18M |
| September 29, 2026 | 126.54M |
| Date | Value |
|---|---|
| September 28, 2026 | 135.22M |
| September 25, 2026 | 126.54M |
| September 24, 2026 | 147.37M |
| September 23, 2026 | 152.58M |
| September 22, 2026 | 168.21M |
| September 21, 2026 | 168.21M |
| September 18, 2026 | 150.85M |
| September 17, 2026 | 169.94M |
| September 16, 2026 | 168.21M |
| September 15, 2026 | 224.62M |
| September 14, 2026 | 230.70M |
| September 11, 2026 | 232.44M |
| September 10, 2026 | 223.76M |
| September 09, 2026 | 230.70M |
| September 08, 2026 | 256.74M |
| September 04, 2026 | 237.64M |
| September 03, 2026 | 229.83M |
| September 02, 2026 | 220.28M |
| September 01, 2026 | 215.08M |
| August 31, 2026 | 213.34M |
| August 28, 2026 | 222.02M |
| August 27, 2026 | 241.12M |
| August 26, 2026 | 244.59M |
| August 25, 2026 | 234.17M |
| August 24, 2026 | 223.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.641B |
| Alnylam Pharmaceuticals, Inc. | 20.56B |
| Anika Therapeutics, Inc. | 246.60M |
| Savara, Inc. | 828.91M |
| Vericel Corp. | 2.005B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.57M |
| Revenue (Quarterly) | 0.50M |
| Total Expenses (Quarterly) | 11.07M |
| EPS Diluted (Quarterly) | -0.05 |
| Profit Margin (Quarterly) | -2.11K% |
| Earnings Yield | -43.17% |
| Normalized Earnings Yield | -45.70 |